ascentage.com (AAPGV): Operatsion rentabellik

AAPGV (Ascentage Pharma Group Ltd) - kompaniyaning tovar belgisi

Ascentage Pharma Group (AAPGV) uchun risklar leykemiya terapiyasida olverembatinibning samaradorligiga bog'liq bo'lib, bu GURU.Markets grafigidagi operatsion marjani belgilaydi, u yerda joriy qiymat -220.00 ni tashkil etadi. Biznesning rivojlanishi apoptoz ingibitorlariga yo'naltirilgan keng ko'lamli R&D investitsiyalariga tayanadi. Hematologlar orasidagi brendning yuqori obro'si va global sherikliklar kompaniyaning onkologiyaga qarshi kurashda sezilarli terapevtik salohiyatini tasdiqlaydi.

AAPGV - ascentage.com Operatsion foyda koeffitsiyenti 25.01.2025 - 19.11.2026 oraligʻida

Ascentage Pharma Group (AAPGV) boʻyicha maʼlumotlarning jamlanma tahliliy kesimlari

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- birja kapitallashuvi ma'lumotlari:
Kompaniyaning fundamental tahlili:Ascentage Pharma Group Ltd
Ascentage tayyor mahsulotlari

Operatsion marja barcha ishlab chiqarish xarajatlari to'langanidan keyin, ammo qarz majburiyatlari va soliqlari hisobga olinishidan oldin qolgan daromad qismini belgilaydi va resurslarni boshqarish samaradorligining ko'rsatkichi bo'lib xizmat qiladi. Ascentage Pharma Group (AAPGV) kompaniyasining operatsion marja grafigini tahlil qilish orqali investor saratonga qarshi va qarishga qarshi dori vositalarini ishlab chiqish xarajatlari qanchalik darajada haqiqiy foydaga aylanishini baholashi va biznes modelining hayotiyligini tasdiqlashi mumkin.

Ascentage Pharma Group raqobatchilari tahlili

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|DCTH - Operatsion faoliyat rentabelligi|YMAB (Y-mAbs Corp) - Operatsion marja|Sotuvning operatsion marjasi Aura Biosciences (AURA)|Operatsion rentabellik Candel Therapeutics Inc. (CADL)|Sotuvning operatsion marjasi Accuray, Inc. ARAY|Operatsion rentabellik sellaslifesciences.com SLS|Operatsion foyda normasi ACTU|CTOR - Operatsion rentabellik|Operatsion faoliyat rentabelligi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operatsion rentabellik|FATE: Operatsion foyda koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Operatsion marja|TCRX (TScan Therapeutics) - Operatsion foyda koeffitsiyenti|Operatsion rentabellik Champions Oncology (CSBR)|Operatsion faoliyat rentabelligi XBiotech USA|Operatsion rentabellik CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Sotuvning operatsion rentabelligi|RADX - Operatsion rentabellik|ARTV - Operatsion marja|Adlai Nortye Ltd (ANL) - Operatsion rentabellik|Veru Pharma - Operatsion foyda normasi|Operatsion rentabellik Tempest Therapeutics Corp|Operatsion foyda bo'yicha sotuv rentabelligi XLO (Xilio Therapeutics, Inc.)|Operatsion marja RENB|MURA (Mural Oncology) - Operatsion foyda normasi|Operatsion marja KAPA (Kairos Pharma Ltd)|OKUR: Operatsion foyda bo'yicha sotuv rentabelligi|GDTC: Sotuvning operatsion marjasi|CRIS - Operatsion marja|APLM: Operatsion marja|Sotuvning operatsion rentabelligi tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Operatsion marja|Operatsion marja Genprex Inc.|Operatsion marja CLDI|Sotuvning operatsion marjasi Sunshine Biopharma, Inc. SBFM|Operatsion marja XBIO (Xenetic Biosciences)|Operatsion foyda normasi SLRX|PPBT - Operatsion rentabellik|AONC (aoncology.com) - Operatsion foyda bo'yicha sotuv rentabelligi|BGNE: Operatsion marja|Checkpoint Therapeutics Inc (CKPT) - Operatsion marja|ELEV (Elevation Oncology Inc.) - Operatsion marja|icadmed.com (ICAD) - Operatsion faoliyat rentabelligi|Operatsion marja IKNA|NTBL (Notable Labs) - Operatsion foyda normasi|Operatsion marja VIRX (Viracta Therapeutics)|Operatsion faoliyat rentabelligi MorphoSys AG (MOR)|NAYA Biosciences Corp - Operatsion marja